

## NEWS RELEASE

### CALLISTO CAPITAL CORP. FILES EARLY WARNING REPORT

**October 28, 2024 – Calgary, Alberta** – On October 28, 2024, Callisto Capital Corp. (“**Callisto**”) completed a transaction with Decibel Cannabis Company Inc. (TSX-V:DB) (the “**Issuer**”), whereby the Issuer acquired AgMedica Bioscience Ltd., a leader in international medical cannabis exports, (the “**Transaction**”) pursuant to an assignment agreement entered into with Callisto in exchange for a \$6.3 million unsecured convertible debenture of the Issuer delivered to Callisto (the “**Convertible Debenture**”). The conversion of the Convertible Debenture into common shares in the capital of the Issuer (each, a “**Common Share**”) is contingent upon the Issuer obtaining each of the following: (i) the final approval of the TSX Venture Exchange (the “**TSXV**”) in respect of the Transaction; and (ii), if applicable, the approval of the disinterested shareholders of the Issuer in accordance with the rules and policies of the TSXV, which approval, if required, is expected to be sought at the Issuer’s upcoming annual and special meeting of shareholders to be held on December 10, 2024 (the “**Meeting**”).

Prior to the completion of the Transaction, the Investor did not own directly, and indirectly any securities of the Issuer. If the Convertible Debenture converts into Common Shares in accordance with its terms, the Issuer may become a “Control Person” (as such term is defined in the rules and policies of the TSXV) of the Issuer. The conversion price per Common Share under the Convertible Debenture is \$0.055. In the event the Control Person approval is not obtained at the Meeting, the Convertible Debenture will no longer be convertible, will begin accruing interest at a rate of 15% per annum, and the principal amount plus interest accrued thereon will be repayable on April 28, 2025.

The Transaction was made in the ordinary course of business, for investment purposes only. The Investor may from time to time acquire additional Common Shares or other securities of the Issuer, dispose of some or all of the existing or additional Common Shares or other securities of the Issuer or may continue to hold the Common Shares or other securities of the Issuer.

This press release is issued pursuant to National Instrument 62-103 - *The Early Warning System and Related Take-Over Bid and Insider Reporting Issues* in connection with the filing of an early warning report under applicable securities laws, a copy of which is available under the SEDAR+ profile of the Issuer at [www.sedarplus.ca](http://www.sedarplus.ca)

NOT FOR DISSEMINATION IN THE UNITED STATES

#### **Disclaimers**

This press release contains “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking information generally means any information about Callisto or the Issuer that is prospective in nature, and often includes words such as "anticipates", "expects", "estimates", "intends" and words and terms of similar substance, including in connection with the Meeting and the approval of the TSXV. Actual results may vary from the forward-looking information in this press release due to certain material risk factors.

Neither Callisto nor the Issuer assumes any obligation to update or revise the forward-looking information in this press release, unless it is required to do so under Canadian securities legislation.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.